InvestorsHub Logo
Followers 3
Posts 249
Boards Moderated 0
Alias Born 03/30/2013

Re: mh22 post# 55

Monday, 03/13/2017 8:20:51 AM

Monday, March 13, 2017 8:20:51 AM

Post# of 236
Look at SUPN and what they did with Oxtellar and Troekndi epilepsy is a nice niche but we need to keep an eye on Teva and their attempt to make it generic in Canada they have until 2023 in USA lets hope Canada goes to 2030 giving them lots of time to grow market.

LAstly the bought placement gives them los of cash now, great entry price now.